As of 2024-12-12, the EV/EBITDA ratio of 10X Genomics Inc (TXG) is -11.92. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TXG's latest enterprise value is 1,548.33 mil USD. TXG's TTM EBITDA according to its financial statements is -129.85 mil USD. Dividing these 2 quantities gives us the above TXG EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 18.9x - 20.9x | 20.5x |
| Forward P/E multiples | 19.0x - 21.7x | 20.4x |
| Fair Price | (17.11) - (19.17) | (18.65) |
| Upside | -206.4% - -219.2% | -216.0% |
| Date | EV/EBITDA |
| 2024-12-10 | -11.99 |
| 2024-12-09 | -11.99 |
| 2024-12-06 | -11.73 |
| 2024-12-05 | -11.13 |
| 2024-12-04 | -11.84 |
| 2024-12-03 | -11.68 |
| 2024-12-02 | -12.29 |
| 2024-11-29 | -11.76 |
| 2024-11-27 | -11.36 |
| 2024-11-26 | -10.93 |
| 2024-11-25 | -11.20 |
| 2024-11-22 | -10.27 |
| 2024-11-21 | -9.32 |
| 2024-11-20 | -9.35 |
| 2024-11-19 | -9.58 |
| 2024-11-18 | -9.22 |
| 2024-11-15 | -9.37 |
| 2024-11-14 | -10.10 |
| 2024-11-13 | -10.83 |
| 2024-11-12 | -11.55 |
| 2024-11-11 | -11.76 |
| 2024-11-08 | -11.51 |
| 2024-11-07 | -12.01 |
| 2024-11-06 | -12.41 |
| 2024-11-05 | -13.10 |
| 2024-11-04 | -12.58 |
| 2024-11-01 | -12.16 |
| 2024-10-31 | -11.88 |
| 2024-10-30 | -12.31 |
| 2024-10-29 | -11.65 |
| 2024-10-28 | -11.72 |
| 2024-10-25 | -11.37 |
| 2024-10-24 | -11.36 |
| 2024-10-23 | -11.01 |
| 2024-10-22 | -11.05 |
| 2024-10-21 | -11.26 |
| 2024-10-18 | -11.33 |
| 2024-10-17 | -10.79 |
| 2024-10-16 | -11.61 |
| 2024-10-15 | -11.77 |
| 2024-10-14 | -12.10 |
| 2024-10-11 | -12.09 |
| 2024-10-10 | -11.54 |
| 2024-10-09 | -16.33 |
| 2024-10-08 | -15.68 |
| 2024-10-07 | -15.42 |
| 2024-10-04 | -15.60 |
| 2024-10-03 | -15.22 |
| 2024-10-02 | -15.70 |
| 2024-10-01 | -16.80 |